边界可切除胰腺癌新辅助治疗的机遇与挑战

Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer:Opportunity and Challenges

胰腺癌在腹部常见恶性肿瘤中预后最差,根治性手术切除是唯一可能治愈的方法。然而,越来越多的研究结果证实新辅助治疗能改善边界可切除胰腺癌(BRPC)的预后。目前,BRPC的主要治疗方式是新辅助治疗后手术切除肿瘤。全文就BRPC新辅助治疗的发展历程、理论基础、化疗方案、疗效评估及手术时机等方面进行综述。

Pancreatic cancer is a common abdominal malignancy with poor prognosis,and radical surgical resection is the only potential curative treatment for pancreatic cancer.However,an increasing number of studies have demonstrated that neoadjuvant therapy is beneficial in patients with borderline resectable pancreatic cancer(BRPC).At present,the main treatment for patients with BRPC is neoadjuvant therapy followed by surgical resection.This article reviews the development,theoretical basis,chemotherapy regimen,efficacy evaluation and operation timing of neoadjuvant therapy for BRPC.